193 related articles for article (PubMed ID: 26320860)
1. Identification and Characterization of an Irreversible Inhibitor of CDK2.
Anscombe E; Meschini E; Mora-Vidal R; Martin MP; Staunton D; Geitmann M; Danielson UH; Stanley WA; Wang LZ; Reuillon T; Golding BT; Cano C; Newell DR; Noble ME; Wedge SR; Endicott JA; Griffin RJ
Chem Biol; 2015 Sep; 22(9):1159-64. PubMed ID: 26320860
[TBL] [Abstract][Full Text] [Related]
2. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated SN2 reactivity of 2,2,2-trifluoroethoxysulfonates.
Wong C; Griffin RJ; Hardcastle IR; Northen JS; Wang LZ; Golding BT
Org Biomol Chem; 2010 May; 8(10):2457-64. PubMed ID: 20448906
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines.
Coxon CR; Anscombe E; Harnor SJ; Martin MP; Carbain B; Golding BT; Hardcastle IR; Harlow LK; Korolchuk S; Matheson CJ; Newell DR; Noble ME; Sivaprakasam M; Tudhope SJ; Turner DM; Wang LZ; Wedge SR; Wong C; Griffin RJ; Endicott JA; Cano C
J Med Chem; 2017 Mar; 60(5):1746-1767. PubMed ID: 28005359
[TBL] [Abstract][Full Text] [Related]
5. Type II Inhibitors Targeting CDK2.
Alexander LT; Möbitz H; Drueckes P; Savitsky P; Fedorov O; Elkins JM; Deane CM; Cowan-Jacob SW; Knapp S
ACS Chem Biol; 2015 Sep; 10(9):2116-25. PubMed ID: 26158339
[TBL] [Abstract][Full Text] [Related]
6. Structural and binding studies of cyclin-dependent kinase 2 with NU6140 inhibitor.
Talapati SR; Goyal M; Nataraj V; Pothuganti M; R SM; Gore S; Ramachandra M; Antony T; More SS; Rao NK
Chem Biol Drug Des; 2021 Nov; 98(5):857-868. PubMed ID: 34423559
[TBL] [Abstract][Full Text] [Related]
7. Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301.
Thomas HD; Wang LZ; Roche C; Bentley J; Cheng Y; Hardcastle IR; Golding BT; Griffin RJ; Curtin NJ; Newell DR
Eur J Cancer; 2011 Sep; 47(13):2052-9. PubMed ID: 21570822
[TBL] [Abstract][Full Text] [Related]
8. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.
Griffin RJ; Henderson A; Curtin NJ; Echalier A; Endicott JA; Hardcastle IR; Newell DR; Noble ME; Wang LZ; Golding BT
J Am Chem Soc; 2006 May; 128(18):6012-3. PubMed ID: 16669651
[TBL] [Abstract][Full Text] [Related]
9. 8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode.
Carbain B; Paterson DJ; Anscombe E; Campbell AJ; Cano C; Echalier A; Endicott JA; Golding BT; Haggerty K; Hardcastle IR; Jewsbury PJ; Newell DR; Noble ME; Roche C; Wang LZ; Griffin RJ
J Med Chem; 2014 Jan; 57(1):56-70. PubMed ID: 24304238
[TBL] [Abstract][Full Text] [Related]
10. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
Elgazwy AS; Ismail NS; Elzahabi HS
Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
[TBL] [Abstract][Full Text] [Related]
11. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
Deng Y; Shipps GW; Zhao L; Siddiqui MA; Popovici-Muller J; Curran PJ; Duca JS; Hruza AW; Fischmann TO; Madison VS; Zhang R; McNemar CW; Mayhood TW; Syto R; Annis A; Kirschmeier P; Lees EM; Parry DA; Windsor WT
Bioorg Med Chem Lett; 2014 Jan; 24(1):199-203. PubMed ID: 24332088
[TBL] [Abstract][Full Text] [Related]
12. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
Zhang G; Ren Y
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
[TBL] [Abstract][Full Text] [Related]
13. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
Pratt DJ; Bentley J; Jewsbury P; Boyle FT; Endicott JA; Noble ME
J Med Chem; 2006 Sep; 49(18):5470-7. PubMed ID: 16942020
[TBL] [Abstract][Full Text] [Related]
14. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.
Vulpetti A; Casale E; Roletto F; Amici R; Villa M; Pevarello P
J Mol Graph Model; 2006 Mar; 24(5):341-8. PubMed ID: 16260160
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Biological Evaluation of N(2) -Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors.
Cortese D; Chegaev K; Guglielmo S; Wang LZ; Golding BT; Cano C; Fruttero R
ChemMedChem; 2016 Aug; 11(16):1705-8. PubMed ID: 27355194
[TBL] [Abstract][Full Text] [Related]
16. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
[TBL] [Abstract][Full Text] [Related]
17. Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure.
Jansa J; Jorda R; Škerlová J; Pachl P; Peřina M; Řezníčková E; Heger T; Gucký T; Řezáčová P; Lyčka A; Kryštof V
Eur J Med Chem; 2021 Apr; 216():113309. PubMed ID: 33711765
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
[TBL] [Abstract][Full Text] [Related]
19. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
Kontopidis G; Andrews MJ; McInnes C; Plater A; Innes L; Renachowski S; Cowan A; Fischer PM
ChemMedChem; 2009 Jul; 4(7):1120-8. PubMed ID: 19472269
[TBL] [Abstract][Full Text] [Related]
20. Structure-based approaches to improve selectivity: CDK2-GSK3beta binding site analysis.
Vulpetti A; Crivori P; Cameron A; Bertrand J; Brasca MG; D'Alessio R; Pevarello P
J Chem Inf Model; 2005; 45(5):1282-90. PubMed ID: 16180905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
